NEW YORK (GenomeWeb News – Sequenom today reported preliminary full-year revenue of $162 million, an increase of 81 percent over the prior year but shy of consensus analyst estimates of $164.4 million.

Alongside its preliminary financial results, the company said that it is expanding its noninvasive prenatal testing menu by developing a "low cost test on an alternative platform" that it plans to launch by the end of the year. Sequenom's MaterniT21 Plus prenatal trisomy test currently runs on the Illumina sequencing platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.